Tango Therapeutics Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$55M
Industry:Biotech
Founded:2017
Lead Investor(s):Third Rock Ventures

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Tango Therapeutics's estimated annual revenue is currently $12.9M per year.
  • Tango Therapeutics received $55.0M in venture funding in March 2017.
  • Tango Therapeutics's estimated revenue per employee is $155,000
  • Tango Therapeutics's total funding is $55M.

Employee Data

  • Tango Therapeutics has 83 Employees.
  • Tango Therapeutics grew their employee count by 38% last year.
  • Tango Therapeutics currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Ultivue
$8.7M56-12%N/AN/A
Ohana Bioscienc...
$8.7M5660%N/AN/A
Compass Therape...
$16.4M10614%N/AN/A
Cell Signaling ...
$89.4M577N/AN/AN/A
Momenta Pharmac...
N/A220N/AN/AN/A
Emulate
$15.3M99-17%N/AN/A
ArQule
N/A94N/AN/AN/A
Hamilton Storag...
$17.2M1119%N/AN/A
Alnylam Pharmac...
$74.9M127731%N/AN/A
Transgenomic
N/A47N/AN/AN/A
Missing a competitor? Contribute!?
Submit

Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today's targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango's programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango's success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.

keywords:N/A

83

Number of Employees

$12.9M

Revenue (est)

1

Current Jobs

38%

Employee Growth %

$55M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
Janid AliVice President, Biochemistry
David GuerinDirector, Chemistry
Patrick McCarrenAssociate Director, Computational Chemistry
Joseph KennedyPrincipal
John MaxwellVp Chemistry
Kevin CottrellDirector Of Medicinal Chemistry
Yi YuAssociate Director - Computational Biology
Douglas WhittingtonDirector of Structural Biology
Caroline Proulx-LafranceDirector Project Management
Lina GuAssociate Director

Tango Therapeutics News

09/03/2019 - Accent Therapeutics Taps Tango's Shakti Narayan for CEO

Narayan comes to Lexington, MA-based Accent from Tango Therapeutics, where he was chief business officer for the past two years.

09/06/2019 - Chutes & Ladders—Bausch Health's Salix loses McKenna to ...

Narayan most recently served as CBO at Tango Therapeutics. Prior to Tango, Narayan was a VP and head of transactions at Johnson ...

09/03/2019 - Accent Therapeutics Appoints Shakti Narayan as Chief ...

Dr. Narayan was most recently Chief Business Officer of Tango Therapeutics, where he was responsible for business development, finance ...

Tango Therapeutics Funding

DateAmountRoundLead InvestorsReference
2017-03-31$55.0MAThird Rock VenturesArticle

Tango Therapeutics Executive Hires

DateNameTitleReference
2017-09-26Barabara WeberCEOArticle
2017-12-07Shakti NarayanChief Business OfficerArticle
2018-05-11Alan HuangChief Scientific OfficerArticle